Reverse Payments by Drug Companies: The Supreme Court Declines to Adopt a Bright-Line Test (PDF)

Select a format

PDF :Electronic, 3 Pages
ISBN: 9781422429983
In Stock
Price
$63.00
QTY
International Order Inquiry

Product details

The Federal Trade Commission has long opposed "reverse payments," the practice by which a pioneer drug company selling a brand-name drug pays a generic drug company to not enter the market. While the FTC has challenged such settlements on several occasions, it has usually lost. On June 17, a bare majority of the Supreme Court ruled in FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013), that neither side was right.

 

Thomas Carey is a partner at Sunstein, Kann, Murphy and Timbers LLP.  His clients rely on his judgment and expertise in strategic matters, particularly those involving capital-raising, licensing, mergers and acquisitions and tax planning.  He advises start-ups and established companies in outsourcing, joint ventures, corporate governance and FDA compliance matters. 

 

Nancy Chiu Wilker, Ph.D. is a partner at Sunstein, Kann, Murphy and Timbers LLP and a member of its Life Sciences Practice Group. She has practiced intellectual property law in both law firm and corporate settings in life sciences since 1997. Nancy handles patent prosecution matters, portfolio development, product clearance, intellectual property due diligence, and agreements involving transfer of intellectual property.

 

Ask the LexisNexis experts - and get a complete answer based on today's law.

 

An authoritative analysis of important cases, codes, statutes, rulings, emerging issues or legal topics is available now - through LexisNexis Emerging Issues Analysis. The brain trust of LexisNexis authors - thousands of recognized authorities who develop the respected Matthew Bender®, Mealey's and Martindale-Hubbell® treatises and articles - produce this highly specific content. Each commentary covers an important case, code, statute, ruling or emerging issue such as subprime, nanotechnology, or climate change. More current and concentrated than treatises and more analytical than news, Emerging Issues Analysis bridges the information gap between the two, providing quick expert analysis of current developments in law.

 

Emerging Issues Analysis PDFs should be purchased individually or accessed through Lexis.com if you have a subscription.

 

(7027)